Liminatus Pharma, Inc. Class A Share Price
NASDAQ: LIMN | Micro Cap$2.81
+$2.81 (--%) Last updated on 29 Oct, 2026 | 20:11 ISTLiminatus Pharma, Inc. Class A Stock Performance
Liminatus Pharma, Inc. Class A Share Price Chart
$2.81$3.04
L
H
About Liminatus Pharma, Inc. Class A
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.
Liminatus Pharma, Inc. Class A Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Oct 2026 | $3.76 | $2.81 | -28.41% |
Sep 2026 | $3.69 | $3.92 | -11.20% |
Aug 2026 | $0.10 | $4.42 | +4,191.26% |
Jul 2026 | $0.10 | $0.10 | -9.65% |
Jun 2026 | $0.17 | $0.11 | -30.91% |
May 2026 | $0.21 | $0.17 | -19.90% |
Apr 2026 | $0.17 | $0.21 | +17.05% |
Mar 2026 | $0.24 | $0.18 | -30.71% |
Feb 2026 | $0.55 | $0.25 | -56.21% |
Jan 2026 | $0.64 | $0.58 | -9.52% |
Dec 2025 | $1.03 | $0.64 | -38.07% |
Nov 2025 | $1.39 | $1.03 | -25.54% |